What is the difference between a dual and a triple agonist?

A dual agonist engages two receptor targets — typically GLP-1 and GIP — while a triple agonist adds glucagon receptor activity to those two.

Which compound is the usual comparator in this class?

Single GLP-1 receptor agonists such as semaglutide are the most heavily characterized and are commonly used as the reference arm in comparative research.

Should a comparison series come from one supplier?

Where possible, yes. Sourcing every arm from one supplier with per-lot analytical reports removes supplier variability as a confounder.

Are these compounds available for human use?

No. Everything listed here is supplied strictly for laboratory research and development, not for human or veterinary use.

GLP-1, Dual, and Triple Agonists Compared

The incretin research series is usually described by how many receptors a molecule engages. This overview compares the single, dual, and triple agonist classes at the receptor level and notes what changes for the researcher handling them.

Updated August 8, 2026

Single GLP-1 receptor agonists

Semaglutide is the reference compound in this class. It engages the GLP-1 receptor alone, and the bulk of the published incretin literature — and therefore the widest body of comparative data — sits here. For a study that needs a well-characterized control arm, a single-receptor agonist is usually the reference point.

Dual GLP-1/GIP agonists

Tirzepatide engages both the GLP-1 and the GIP receptor. Adding GIP activity changes the signaling profile relative to a GLP-1-only comparator, which is precisely why dual agonists are studied against single agonists rather than in isolation. Cagrilintide-semaglutide combinations are studied on a different axis, pairing an amylin-analog mechanism with GLP-1 activity.

Triple GLP-1/GIP/glucagon agonists

Retatrutide adds glucagon receptor activity to the dual profile. The glucagon arm is what distinguishes it mechanistically and what makes it the most complex of the three classes to interpret, because three receptor systems contribute to any observed effect. Survodutide and mazdutide occupy adjacent positions in the glucagon-containing space.

What changes at the bench

Comparative studies need matched handling across arms — same diluent, same storage, same freeze–thaw history
Net peptide content differs between lots and compounds; concentration should be computed from it, not gross vial mass
Longer-acting analogs and shorter-acting ones are not interchangeable on a study timeline
Lot-to-lot consistency matters more in multi-arm work than absolute purity on any single lot

Sourcing across a comparison series

Running a multi-compound comparison from multiple suppliers introduces a variable you cannot control for. Sourcing the series from one supplier with per-lot documentation keeps the analytical baseline consistent across arms.

All compounds are sold strictly for laboratory research and development. They are not for human or veterinary use, and nothing on this page is medical advice.

Frequently asked questions

What is the difference between a dual and a triple agonist?: A dual agonist engages two receptor targets — typically GLP-1 and GIP — while a triple agonist adds glucagon receptor activity to those two.
Which compound is the usual comparator in this class?: Single GLP-1 receptor agonists such as semaglutide are the most heavily characterized and are commonly used as the reference arm in comparative research.
Should a comparison series come from one supplier?: Where possible, yes. Sourcing every arm from one supplier with per-lot analytical reports removes supplier variability as a confounder.
Are these compounds available for human use?: No. Everything listed here is supplied strictly for laboratory research and development, not for human or veterinary use.